ReShape Lifesciences® to Present at the Q2 Virtual Investor Summit
15 3월 2023 - 9:30PM
ReShape Lifesciences Inc. (Nasdaq:
RSLS), the premier physician-led weight loss and metabolic
health solutions company, today announced that Paul F. Hickey,
President and Chief Executive Officer, and Tom Stankovich, Chief
Financial Officer, will present a company overview at the Q2
Virtual Investor Summit on Wednesday, March 29 at 1:00 pm ET.
During the virtual presentation, management will highlight the
Company’s three pillars for growth and its portfolio of products
that address the entire weight loss continuum including the
anatomy-sparing Lap-Band®.
ReShape Lifesciences’ management team will be
available for one-on-one meetings during the Investor Summit. The
conference is complimentary to qualified investors. Please register
through the Complimentary Investor Registration. To schedule a
meeting with management outside of the conference, contact Michael
Miller with Rx Communications at mmiller@rxir.com.
A live webcast of the Investor Summit
presentation will be available on the “Events and Presentations”
section of ReShape’s website at:
https://ir.reshapelifesciences.com/events-and-presentations. An
archived replay will be available on the company’s website for a
period of 90 days after the conference.
About ReShape Lifesciences
Inc.ReShape Lifesciences® is America’s premier weight loss
and metabolic health-solutions company, offering an integrated
portfolio of proven products and services that manage and treat
obesity and metabolic disease. The proprietary, FDA-approved,
Lap-Band® Program provides minimally invasive, long-term treatment
of obesity and is an alternative to more invasive surgical stapling
procedures such as the gastric bypass or sleeve gastrectomy.
ReShapeCare™ is a virtual weight-management program that supports
lifestyle changes for all weight loss patients led by
board-certified health coaches to help them keep the weight off
over time. The recently launched ReShape Marketplace™ is an online
collection of quality wellness products curated for all consumers
to help them achieve their health goals. The investigational
Diabetes Bloc-Stim Neuromodulation™ (DBSN™) system utilizes a
proprietary vagus nerve block and stimulation technology platform
for the treatment of Type 2 diabetes and metabolic disorders. The
patented, Obalon® balloon technology is a non-surgical,
swallowable, gas-filled intra-gastric balloon that is designed to
provide long-lasting weight loss. For more information, please
visit www.reshapelifesciences.com.
CONTACTSReShape Lifesciences Investor
Contact:Thomas StankovichChief Financial
Officer949-276-6042ir@ReShapeLifesci.com
Investor Relations Contact:Rx
Communications GroupMichael
Miller(917)-633-6086mmiller@rxir.com
ReShape Lifesciences (NASDAQ:RSLS)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
ReShape Lifesciences (NASDAQ:RSLS)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024